Clinical Trials Logo

Cerebral Infarction clinical trials

View clinical trials related to Cerebral Infarction.

Filter by:
  • Active, not recruiting  
  • « Prev · Page 5

NCT ID: NCT01378468 Active, not recruiting - Clinical trials for First Ischemic Stroke

Prognostic Impact of an Oral Triglyceride Tolerance Test in Patients After Acute Ischemic Stroke

Start date: January 2009
Phase: N/A
Study type: Observational

Non-fasting triglyceride levels are thought to play a role in stroke. The investigators hypothesise that the results of a standardised oral triglyceride tolerance test in the subacute setting (3-7 days) after the first ischaemic stroke are associated with the risk of recurrent stroke within 12 months after the index event.

NCT ID: NCT00642213 Active, not recruiting - Ischemic Stroke Clinical Trials

A Comparison of Hemorrhagic and Ischemic Strokes Among Blacks and Whites

GCNKSS
Start date: July 1993
Phase:
Study type: Observational

Our primary goal is to study temporal trends in the incidence rate, causes, treatment, and outcome of stroke among a large biracial metropolitan population of 1,349,351, of whom 215,611 (15%) are black (2000 Census). Such data are critical for the planning, intervention, and evaluation of public health efforts to decrease the mortality and morbidity due to stroke in the United States. We have completed this goal for 1993-94, 1999, 2005, 2010 and 2015. We are in the process of collecting this data for 2020. In the 2020 study period we will also be ascertaining 3 year recurrence rates for all incident stroke events.

NCT ID: NCT00004732 Active, not recruiting - Stroke Clinical Trials

Carotid Revascularization Endarterectomy Versus Stenting Trial

CREST
Start date: December 2000
Phase: Phase 3
Study type: Interventional

The purpose of the Carotid Revascularization Endarterectomy versus Stenting Trial (CREST) is to compare the relatively new procedure of stent-assisted carotid angioplasty (CAS) to the traditional and accepted surgical approach of carotid endarterectomy (CEA) for the treatment of carotid artery stenosis to prevent recurrent strokes in those patients who have had a TIA (transient ischemic attack) or a mild stroke within the past 6 months (symptomatic) and in those patients who have not had any symptoms within the past 6 months (asymptomatic).